Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Dermatologic 1

Conditions

Melanoma 3Carcinoma, Renal Cell 2Uveal Melanoma 1Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia 1Kidney Neoplasms 1

Interventions

Cyclophosphamide 16aldesleukin 14fludarabine 12fludarabine phosphate 11Interleukin-2 10montanide ISA 51 3Whole-Body Irradiation 2Radiation 2MART-1 Antigen 2Gefitinib 2sargramostim 1pembrolizumab 1peginterferon alfa-2a 1incomplete Freund's adjuvant 1flt3 ligand protein 1endonuclease V, phage T4 1Surgical Procedures, Operative 1Semaxinib 1Radiotherapy 1Peptides 1Lapatinib 1Interleukin-15 1Interleukin-12 1Early Intervention, Educational 1Deoxyribonuclease (Pyrimidine Dimer) 1Dasatinib 1Congresses as Topic 1Cholecalciferol 1B3(Fv)-PE38KDEL recombinant immunotoxin 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Skin Neoplasms × flt3 ligand protein × Clear all
NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡